Deep learning for prediction of colorectal cancer outcome: a discovery and validation study

[1]  N. Razavian,et al.  Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.

[2]  A. Briggs,et al.  3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial , 2018, The Lancet. Oncology.

[3]  R. Labianca,et al.  Duration of Adjuvant Chemotherapy for Stage III Colon Cancer , 2018, The New England journal of medicine.

[4]  Jeffrey A. Moscow,et al.  The evidence framework for precision cancer medicine , 2018, Nature Reviews Clinical Oncology.

[5]  Dmitrii Bychkov,et al.  Deep learning based tissue analysis predicts outcome in colorectal cancer , 2018, Scientific Reports.

[6]  I Tomlinson,et al.  Prognostic markers for colorectal cancer: estimating ploidy and stroma , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  D. Brat,et al.  Predicting cancer outcomes from histology and genomics using convolutional networks , 2017, Proceedings of the National Academy of Sciences.

[8]  Andrew H. Beck,et al.  Diagnostic Assessment of Deep Learning Algorithms for Detection of Lymph Node Metastases in Women With Breast Cancer , 2017, JAMA.

[9]  Wei Luo,et al.  Guidelines for Developing and Reporting Machine Learning Predictive Models in Biomedical Research: A Multidisciplinary View , 2016, Journal of medical Internet research.

[10]  D. Kerr,et al.  Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. , 2016, The Lancet. Oncology.

[11]  Brendan J. Frey,et al.  Classifying and segmenting microscopy images with deep multiple instance learning , 2015, Bioinform..

[12]  C. Tournigand,et al.  Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Adam Kiezun,et al.  Whole-exome sequencing and clinical interpretation of FFPE tumor samples to guide precision cancer medicine , 2013, Nature Medicine.

[14]  C. Yau,et al.  Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations , 2013, The American Journal of Gastroenterology.

[15]  D. Kerr,et al.  Biological markers: Tailoring treatment and trials to prognosis , 2013, Nature Reviews Clinical Oncology.

[16]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration , 2012, BMC Medicine.

[17]  D. Kerr,et al.  Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  D. Kerr,et al.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine , 2011, Nature Reviews Clinical Oncology.

[19]  D. Kerr,et al.  Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  L. V. van't Veer,et al.  Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  N. Shepherd,et al.  How important is peritoneal involvement in rectal cancer? A prospective study of 331 cases , 2010, Histopathology.

[22]  D. Kerr,et al.  Phase III randomized trial assessing rofecoxib in the adjuvant setting of colorectal cancer: final results of the VICTOR trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  F. Sinicrope.  DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer , 2010, Nature Reviews Clinical Oncology.

[24]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[26]  Quasar Collaborative Group.  Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study , 2007, The Lancet.

[27]  J. Nesland,et al.  Expression and gene amplification of primary (A, B1, D1, D3, and E) and secondary (C and H) cyclins in colon adenocarcinomas and correlation with patient outcome , 2005, Journal of Clinical Pathology.

[28]  N. Shepherd,et al.  Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer , 2002, Gut.

[29]  D. Kerr,et al.  Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial , 2000, The Lancet.